46. 悪性関節リウマチ Malignant rheumatoid arthritis Clinical trials / Disease details


臨床試験数 : 4,356 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

  
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05447520
(ClinicalTrials.gov)
July 15, 20221/7/2022Montelukast Use in Rheumatoid ArthritisClinical Study Evaluating the Efficacy and Safety of Adjunctive Use of Montelukast in Rheumatoid Arthritis PatientsRheumatoid ArthritisDrug: Montelukast;Drug: Placebo;Drug: Conventional DMARDsNoha MansourNULLRecruiting18 Years80 YearsAll50Phase 2Egypt
2NCT03770923
(ClinicalTrials.gov)
October 1, 20187/12/2018Effect of Some Drugs on Rheumatoid Arithritis ActivityClinical Study Evaluating the Effect of Histamine 1 Receptor Antagonist and Leukotreine Receptor Antagonist on Patients With Rheumatoid ArithritisRheumatoid ArthritisDrug: Rupatadine;Drug: MontelukastSherief Abd-ElsalamNULLRecruiting18 YearsN/AAll75Phase 3Egypt
3NCT03131973
(ClinicalTrials.gov)
May 13, 201725/4/2017Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and PravastatinEffects of Concomitant Administration of BMS-986195 on the Single-dose Pharmacokinetics of Methotrexate and Probe Substrates for Cytochrome P450 1A2, 2C8, 2C9, 2C19, 3A4, Organic Anion Transporter Polypeptide 1B1 and P-glycoprotein in Healthy ParticipantsRheumatoid ArthritisDrug: BMS-986195;Drug: Methotrexate;Drug: Leucovorin;Drug: Caffeine;Drug: Montelukast;Drug: Flurbiprofen;Drug: Omeprazole;Drug: Midazolam;Drug: Digoxin;Drug: PravastatinBristol-Myers SquibbNULLCompleted18 Years50 YearsAll26Phase 1United States
4NCT02762123
(ClinicalTrials.gov)
May 20163/5/2016A Study to Assess the Effect of BMS-986142 on Pharmacokinetics (PK) of Probe SubstratesEffects of Concomitant Administration of BMS-986142 on the Single-dose Pharmacokinetics of Probe Substrates for CYP2C8, CYP2C9, CYP2C19, CYP3A4, and P-gp in Healthy SubjectsRheumatoid ArthritisDrug: BMS-986142 200mg;Drug: BMS Drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin);Drug: BMS-986142 350mgBristol-Myers SquibbNULLCompleted18 Years50 YearsBoth28Phase 1United States
5NCT02456844
(ClinicalTrials.gov)
May 201527/5/2015Study to Investigate the Effect of BMS-986142 on the Pharmacokinetics (PK) of Methotrexate and Probe Substrate Cocktail in Healthy PatientsEffects of BMS-986142 on the Single-dose Pharmacokinetics of Methotrexate and Probe Substrates Montelukast (CYP2C8), Flurbiprofen (CYP2C9), Midazolam (CYP3A4), Digoxin (P-gp), and Pravastatin (OATP1B1) in Healthy SubjectsRheumatoid ArthritisDrug: Montelukast, Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142;Drug: Methotrexate, Leucovorin and BMS-986142Bristol-Myers SquibbNULLCompleted18 Years50 YearsBoth24Phase 1NULL